ClinicalTrials.gg
TerminatedNCT06520202Updated Sep 29, 2025

RHPRG4 FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

A Phase 1/2 interventional study of rhPRG4 (450 µg/mL) and Vehicle in Sjogren's Syndrome With Dry Eye, sponsored by Lubris Bio Pty Ltd. Terminated at 1 site in Australia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-29.

Sponsored by Lubris Bio Pty Ltd · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Efficacy signal substantial enough to move to a larger sturdy

From the registry’s dates

  • Primary completion was Nov 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Sjogren's Syndrome with a site in Australia — 7 open to participants now, 11 under way, 6 of them phase 3. Sjogren's Syndrome · Australia.

Enrollment
18th of 18
8 · median 240
Started
2024
with 2 others
Phase 1/2
Only one
of the 18
Registered
11th of 18
by date
Lead sponsor
2 of 18
Lubris Bio Pty Ltd

Among the 18 studies in Sjogren's Syndrome with a site in Australia, this one is the 18th largest by enrollment, is one of 3 that started in 2024, is the only one in phase 1/2, and was the 11th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

7 of the 18 studies in Sjogren's Syndrome with a site in Australia are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Sjogren's Syndrome with a site in Australia, or all of them as a file.
02

Study summary

A 1-day, randomized (1:1) controlled, masked, pre-market study. Subjects with moderate to severe Sjögren's related Dry Eye Disease will be evaluated at 0, 5, 30 \& 90 minutes post dose of either rhPRG4 (Treatment group) or vehicle (Crossover group). At 90 minutes, Crossover group subjects will be administered rhPRG4, then evaluated 5 \& 30 minutes after rhPRG4 instillation (95 \& 120 minutes from baseline). All subjects will self-report for the remainder of the day at 4 hours and 8 hours post dose.

03

Conditions studied

  • Sjogren's Syndrome With Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects 18-75 years of age.
  2. Subjects previously diagnosed with Sjögren's Syndrome
  3. Subjects diagnosed with Sjögren's related Dry Eye Disease for at least 3 months (current use of artificial tears for the treatment of Dry Eye)
  4. VAS Eye Dryness (100-point scale) score ≥ 45 mm;
  5. Osmolarity ≥ 312 mOsm/L in the worst performing eye;
  6. Only subjects who satisfy all requirements may be included in the study.

Exclusion criteria

Exclusion Criteria:

Diagnosis and Main Criteria for Exclusion:

  1. Evidence of an active ocular infection in either eye;
  2. History or presence of ocular surface disorders not related to dry eye in either eye, including but not limited to significant conjunctivochalasis, SLK, limbal stem cell deficiency, allergic conjunctivitis, GPC, AKC, anterior basement membrane dystrophies, recurrent corneal erosion, neurotrophic keratitis, PCEDs, exposure keratitis and moderate to severe blepharitis;
  3. History of any ocular surgery (including laser or refractive surgical procedures) in either eye within 30 days before study enrollment. Ocular surgery will not be allowed during the study treatment period and elective ocular surgery procedures should not be planned during the duration of the follow-up period;
  4. Presence or history of any ocular or systemic disorder or condition that might significantly hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the investigator to be incompatible with the study visit schedule or conduct of trial procedures (e.g. ocular trauma, progressive or degenerative corneal conditions, uveitis, systemic infection), or initiation or cessation any systemic drug during the study period that is known to induce dry eye disease;
  5. Known to one of the components of the study or procedural medications;
  6. Participation in another clinical study at the same time as the present study or within 14 days of screening/baseline visit;
  7. History of drug, medication or alcohol abuse or addiction;
  8. Females of (those who are not surgically sterilized or for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:
  9. are currently pregnant or,
  10. have a positive result on the urine pregnancy test at the Screening/Baseline Visit or,
  11. intend to become pregnant during the entire course of and 30 days after the study treatment periods, or,
  12. are breast-feeding or,
  13. not willing to use highly effective measures, such as: Hormonal contraceptives - oral, implanted, transdermal, or injected and/or mechanical barrier methods, during the entire course of and 30 days after the study treatment periods.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Treatment Group

    Drug: rhPRG4 (450 µg/mL)

  • Active comparator
    Vehicle Group

    Drug: Vehicle

  • Experimental
    Crossover Group

    Drug: rhPRG4 (450 µg/mL)

Interventions

  • DrugrhPRG4 (450 µg/mL)

    1-2 drops of rhPRG4 450 µg/mL solution in both eyes

  • DrugVehicle

    Sterile isotonic aqueous solution for ocular administration containing 0.01% polysorbate 20.

06

What researchers measure

Primary outcomes

  1. • To assess the efficacy of rhPRG4 using the average VAS score assessing subjects' eye dryness (Question: Rate the dryness of your eye; anchors: 0 = no discomfort, 100 = maximal discomfort) at 90 minutes

    Time frame: 90 minutes

  2. • To assess the safety of rhPRG4 by observation of the severity of treatment-emergent adverse events

    Time frame: 90 minutes

Secondary outcomes

  1. • To assess the efficacy of rhPRG4 using the average VAS score for dryness, foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision and photophobia and total VAS

    Time frame: at 5 minutes, 30 minutes, 90 minutes, 4 & 8 hours

  2. • To assess the efficacy of rhPRG4 using the minimum inter-eye non-invasive tear film breakup time (TBUT): min(OU)

    Time frame: 30 minutes, 90 minutes

  3. • To assess the efficacy of rhPRG4 using maximum inter-eye tear osmolarity: max(OU)

    Time frame: 30 minutes, 90 minutes

  4. • To assess the efficacy of rhPRG4 using a patient questionnaire

    Time frame: 90 minutes

  5. • To assess the safety of rhPRG4 by observation of the Best Corrected Visual Acuity (BCVA)

    Time frame: 90 minutes

  6. • To assess the safety of rhPRG4 by observation of signs evaluated by slit lamp examination (SLE)

    Time frame: 90 minutes

07

Study locations

1 site
  • Sydney Eye Hospital
    Sydney, Australia
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Nov 2024, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2024
First posted
Jul 25, 2024
StartActual
Nov 5, 2024
Primary completionActual
Nov 11, 2024
CompletionActual
Nov 11, 2024
Last update
Sep 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06520202
Lead sponsor
Lubris Bio Pty Ltd
Responsible party
Sponsor
First posted
Jul 25, 2024
Start date
Nov 5, 2024
Primary completion
Nov 11, 2024
Completion
Nov 11, 2024
Last update
Sep 29, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion